ALT
Price
$6.86
Change
+$0.15 (+2.24%)
Updated
Jan 17 closing price
Capitalization
487.91M
67 days until earnings call
ARTH
Price
$0.25
Change
+$0.06 (+31.58%)
Updated
Jan 17 closing price
Capitalization
1.11M
Ad is loading...

ALT vs ARTH

Header iconALT vs ARTH Comparison
Open Charts ALT vs ARTHBanner chart's image
Altimmune
Price$6.86
Change+$0.15 (+2.24%)
Volume$1.7M
Capitalization487.91M
Arch Therapeutics
Price$0.25
Change+$0.06 (+31.58%)
Volume$5.91K
Capitalization1.11M
ALT vs ARTH Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. ARTH commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and ARTH is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (ALT: $6.86 vs. ARTH: $0.25)
Brand notoriety: ALT and ARTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 51% vs. ARTH: 73%
Market capitalization -- ALT: $487.91M vs. ARTH: $1.11M
ALT [@Biotechnology] is valued at $487.91M. ARTH’s [@Biotechnology] market capitalization is $1.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $352.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileARTH’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • ARTH’s FA Score: 0 green, 5 red.
According to our system of comparison, ALT is a better buy in the long-term than ARTH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 3 TA indicator(s) are bullish.

  • ALT’s TA Score: 3 bullish, 4 bearish.

Price Growth

ALT (@Biotechnology) experienced а -0.15% price change this week, while ARTH (@Biotechnology) price change was +46.97% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.65%, and the average quarterly price growth was -1.89%.

Reported Earning Dates

ALT is expected to report earnings on May 20, 2025.

ARTH is expected to report earnings on Aug 30, 2023.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($488M) has a higher market cap than ARTH($1.11M). ARTH YTD gains are higher at: 47.059 vs. ALT (-4.854).
ALTARTHALT / ARTH
Capitalization488M1.11M43,924%
EBITDA-103.19MN/A-
Gain YTD-4.85447.059-10%
P/E RatioN/AN/A-
Revenue52KN/A-
Total Cash139MN/A-
Total Debt1.77MN/A-
FUNDAMENTALS RATINGS
ALT vs ARTH: Fundamental Ratings
ALT
ARTH
OUTLOOK RATING
1..100
5615
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6395
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARTH's Valuation (87) in the null industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that ARTH’s stock grew similarly to ALT’s over the last 12 months.

ALT's Profit vs Risk Rating (79) in the Miscellaneous Commercial Services industry is in the same range as ARTH (100) in the null industry. This means that ALT’s stock grew similarly to ARTH’s over the last 12 months.

ALT's SMR Rating (98) in the Miscellaneous Commercial Services industry is in the same range as ARTH (100) in the null industry. This means that ALT’s stock grew similarly to ARTH’s over the last 12 months.

ALT's Price Growth Rating (63) in the Miscellaneous Commercial Services industry is in the same range as ARTH (95) in the null industry. This means that ALT’s stock grew similarly to ARTH’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as ARTH (100) in the null industry. This means that ALT’s stock grew similarly to ARTH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALT
RSI
ODDS (%)
Bullish Trend 5 days ago
84%
Stochastic
ODDS (%)
N/A
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
N/A
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
88%
Advances
ODDS (%)
Bullish Trend 11 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
83%
Aroon
ODDS (%)
Bearish Trend 5 days ago
89%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with CLDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
+2.24%
CLDX - ALT
46%
Loosely correlated
+4.48%
KRYS - ALT
46%
Loosely correlated
+2.47%
DNLI - ALT
42%
Loosely correlated
+1.20%
VERV - ALT
42%
Loosely correlated
+0.66%
PLRX - ALT
42%
Loosely correlated
-3.36%
More

ARTH and

Correlation & Price change

A.I.dvisor tells us that ARTH and ALT have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARTH and ALT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARTH
1D Price
Change %
ARTH100%
+28.21%
ALT - ARTH
24%
Poorly correlated
+2.24%
EVGN - ARTH
20%
Poorly correlated
+10.35%
AAVXF - ARTH
12%
Poorly correlated
N/A
BIVI - ARTH
11%
Poorly correlated
+0.45%
APLIF - ARTH
11%
Poorly correlated
N/A
More